Peptide drugs have attracted substantial investment and commercial attention; growth estimates vary materially with the market definition used. Depending on how broadly "peptide" is defined, the global market sat between roughly $68 billion and $141 billion in 2025. The narrower, therapeutically-focused figure (≈$68–75B, excluding traditional insulins) and the broad Grand View Research estimate (≈$140.9B, including established insulin products) both point the same direction: double-digit growth, with a projected CAGR of 8.7%–18% through the early 2030s. The gap between the two numbers is not a contradiction — it is a reminder that "peptide market size" means different things to different analysts, and B2B buyers should always ask which scope a forecast covers.
Several cited market analyses identify the GLP-1 receptor agonist class as a major reported driver. Within the scopes used by the cited analyses, GLP-1 products are estimated at roughly 45%–51% of the peptide therapeutics market, and the four blockbusters — Mounjaro, Ozempic, Zepbound and Wegovy — together exceeded $68B in 2025. Demand is spreading beyond type-2 diabetes and obesity into chronic kidney and liver disease, cardiovascular protection and even neurodegenerative research, which widens the addressable patient pool and lengthens the commercial runway for peptide APIs.
Regionally the market is tri-polar. North America led with about 46.9% of 2025 revenue (≈$35B), followed by Europe at ≈24% and an Asia-Pacific region growing fastest on the back of rising diabetes prevalence in China and India. On the supply side, global peptide API capacity reached ≈48 tonnes in 2025, with China's share climbing to ≈32% and India at ≈18%, while Western producers retained control of the highest-value, GMP-critical segments.
For B2B buyers, one material structural consideration is available manufacturing capacity. The peptide and oligonucleotide CDMO market is forecast to grow from $2.42B (2025) to $2.7B (2026) and past $4B by 2030, with Bachem, PolyPeptide, CordenPharma and AmbioPharm holding roughly 55%–60% of revenue. Demand for GLP-1 agonists and siRNA is outpacing available GMP suite capacity, handing CDMOs unusual pricing power in multi-year capacity contracts. Translation: secure manufacturing reservations early, and treat lead-time and capacity allocation as a core part of supplier selection — not an afterthought.
B2B buyer takeaways
- Always clarify market-size scope (narrow therapeutic vs. broad incl. insulin) before quoting a number internally.
- GLP-1 is the demand engine; expect sustained API demand well beyond diabetes/obesity into nephro, hepatic and cardio indications.
- For some programs, qualified manufacturing capacity may be a more immediate constraint than molecule discovery.
- Consider discussing capacity reservations early where forecasts, qualification requirements and commercial terms justify it.
- China and India are gaining API share; diversify sourcing but vet GMP/quality systems rigorously.
Sources & References
1. 产业世界, "全球多肽药物行业技术发展及市场调研报告 (2026)" https://m.inwwin.com.cn/80/view-1158288-1.html
2. PW Consulting, "Worldwide Polypeptide Drug Market 2026" https://pmarketresearch.com/?p=2603425/
3. PW Consulting, "Worldwide Injectable Peptides Market 2026" https://pmarketresearch.com/?p=2339198/
4. Peptide News Digest, "Market-Forecast News & Research" https://peptidenewsdigest.org/tag/market-forecast
5. 三个皮匠报告, market-size scope comparison (Grand View / IMARC / Research Nester) https://www.sgpjbg.com/searchtag/25988947.html
Editorial summary of third-party reporting only; not legal, medical, investment or regulatory advice. Figures, market estimates and regulatory statements reflect the cited source and publication date, and should be rechecked for the relevant product, jurisdiction and intended use.